Last reviewed · How we verify
Standard IIV4
Standard IIV4 is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus.
Standard IIV4 is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus. Used for Seasonal influenza prevention in adults and children ≥6 months of age.
At a glance
| Generic name | Standard IIV4 |
|---|---|
| Also known as | Flulaval Quadrivalent |
| Sponsor | Marshfield Clinic Research Foundation |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated (killed) influenza virus particles representing two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages. When administered, it triggers both humoral and cellular immune responses, leading to the production of neutralizing antibodies and T-cell mediated immunity against the included viral strains, thereby providing protection against seasonal influenza infection.
Approved indications
- Seasonal influenza prevention in adults and children ≥6 months of age
Common side effects
- Injection site soreness
- Injection site erythema
- Injection site swelling
- Myalgia
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- Randomized Influenza Vaccine Evaluation of Immune Response (PHASE4)
- Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years (PHASE3)
- Influenza Vaccine Responses as a Means of Assessing Immune Competence in Chimeric Kidney/Stem Cell Transplant Recipients
- Simultaneous mRNA COVID-19 and IIV4 Vaccination Study (PHASE4)
- Safety of RIV4 Versus IIV4 in Pregnant Women (PHASE4)
- Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard IIV4 CI brief — competitive landscape report
- Standard IIV4 updates RSS · CI watch RSS
- Marshfield Clinic Research Foundation portfolio CI